Ovarian cancer immunotherapy: opportunities, progresses and challenges

被引:0
|
作者
Bei Liu
John Nash
Carolyn Runowicz
Helen Swede
Richard Stevens
Zihai Li
机构
[1] University of Connecticut School of Medicine,Department of Immunology
[2] University of Connecticut School of Medicine,Neag Comprehensive Cancer Center
[3] University of Connecticut School of Medicine,Department of Community Medicine & Health Care
关键词
Ovarian Cancer; Treg Cell; Epithelial Ovarian Cancer; Dendritic Cell Vaccine; Tumor Cell Vaccine;
D O I
暂无
中图分类号
学科分类号
摘要
Due to the low survival rates from invasive ovarian cancer, new effective treatment modalities are urgently needed. Compelling evidence indicates that the immune response against ovarian cancer may play an important role in controlling this disease. We herein summarize multiple immune-based strategies that have been proposed and tested for potential therapeutic benefit against advanced stage ovarian cancer. We will examine the evidence for the premise that an effective therapeutic vaccine against ovarian cancer is useful not only for inducing remission of the disease but also for preventing disease relapse. We will also highlight the questions and challenges in the development of ovarian cancer vaccines, and critically discuss the limitations of some of the existing immunotherapeutic strategies. Finally, we will summarize our own experience on the use of patient-specific tumor-derived heat shock protein-peptide complex for the treatment of advanced ovarian cancer.
引用
收藏
相关论文
共 50 条
  • [1] Ovarian cancer immunotherapy: opportunities, progresses and challenges
    Liu, Bei
    Nash, John
    Runowicz, Carolyn
    Swede, Helen
    Stevens, Richard
    Li, Zihai
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [2] Immunotherapy opportunities and challenges in ovarian cancer
    Coukos, George
    CLINICAL CANCER RESEARCH, 2013, 19
  • [3] Immunotherapy in ovarian cancer: Challenges and novel opportunities.
    Zamarin, Dmitriy
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 24 - 25
  • [4] Opportunities in immunotherapy of ovarian cancer
    Coukos, G.
    Tanyi, J.
    Kandalaft, L. E.
    ANNALS OF ONCOLOGY, 2016, 27 : 11 - 15
  • [5] Immunotherapy opportunities in ovarian cancer
    Chu, Christina S.
    Kim, Sarah H.
    June, Carl H.
    Coukos, George
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (02) : 243 - 257
  • [6] Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities
    Bashash, Davood
    Zandi, Zahra
    Kashani, Bahareh
    Pourbagheri-Sigaroodi, Atieh
    Salari, Sina
    Ghaffari, Seyed H.
    JOURNAL OF CELLULAR PHYSIOLOGY, 2022, 237 (01) : 346 - 372
  • [7] Pediatric Cancer Immunotherapy: Opportunities and Challenges
    Mary Frances Wedekind
    Nicholas L. Denton
    Chun-Yu Chen
    Timothy P. Cripe
    Pediatric Drugs, 2018, 20 : 395 - 408
  • [8] Immunotherapy in prostate cancer: challenges and opportunities
    Noguchi, Masanori
    Koga, Noriko
    Moriya, Fukuko
    Itoh, Kyogo
    IMMUNOTHERAPY, 2016, 8 (01) : 69 - 77
  • [9] Pediatric Cancer Immunotherapy: Opportunities and Challenges
    Wedekind, Mary Frances
    Denton, Nicholas L.
    Chen, Chun-Yu
    Cripe, Timothy P.
    PEDIATRIC DRUGS, 2018, 20 (05) : 395 - 408
  • [10] Challenges and Opportunities for Pancreatic Cancer Immunotherapy
    Bear, Adham S.
    Vonderheide, Robert H.
    O'Hara, Mark H.
    CANCER CELL, 2020, 38 (06) : 788 - 802